Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This study investigated the contribution of pain to psychiatric symptoms in 43 hospitalized children and adolescents referred for psychiatric evaluation in a pediatric cancer center during a 1-yr period. Procedures included determination of the primary reason for referral, child and parent diagnostic interviews assessing pain history and psychiatric symptoms, and recommendations for improved pain control or other types of intervention and followup. Across the four referral categories (for symptoms of depression, cognitive/perceptual disturbance, anxiety, or disruptive behavior), approximately 20% of all consultations resulted in a primary recommendation for improved pain control. The findings suggest that pediatric cancer pain may go untreated when its manifestations are psychiatric. Implications for staff education, consultation-liaison psychiatry, and psychiatric nosology are discussed.
 ...
PMID:Psychiatric symptoms of pediatric cancer pain. 260 80

A psychoticism questionnaire was designed constituting 110 questions framed on the basis of the following constructs: desocialization, paranoia, thought disorder, depression, perceptual disturbance, superstitions and mania. In the initial tryout, it was administered to 40 psychotics, 40 neurotics and 40 normals and 40 items inadequately discriminating between psychotics and normals/neurotics were deleted. The revised questionnaire was administered, in second tryout, to 50 psychotics, 50 neurotics and 50 normals. The results were again subjected to item analysis and 10 more items were deleted as they could not discriminate significantly between neurotics and psychotics or where they discriminated between normals and neurotics. Kuder-Richardson formula 20 was used for reliability and criterion validity was assessed by comparing the three diagnositic groups with one another. Both these were satisfactory. Thus a psychoticism questionnaire of 60 items was constructed.
 ...
PMID:A psychoticism scale in hindi : I. Construction and initial tryouts. 2205 70

Major depressive disorder (MDD) is a common, serious, debilitating condition affecting 350 million people worldwide, which remains to be unsatisfactorily treated with 53% of patients still complaining of symptoms after completing their courses with the correct dosage. Ketamine, which was approved by the Food and Drug Administration in 2019, is a potential treatment option for those recalcitrant cases. The mechanism of ketamine is not fully understood, but as type it is classified as an N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, and can be given intravenously, intranasally and orally. It is used to treat treatment-resistant depression, depression associated with suicidal ideation, mood and anxiety disorders and depressions associated with either type of bipolar disorder. Although ketamine is considered relatively safe, several side effects have been reported with the major ones being psychiatric in the form of worsening mood, anxiety and agitation; psychotomimetic in the form of dissociation, perceptual disturbance and abnormal sensations; cardiovascular in the form of increased blood pressure and increased heart rate; and neurological in the form of headache and dizziness. Ketamine is still not approved worldwide for usage in patients with treatment-resistant MDD, but if it is approved sometime in the future with relatively fewer side effects, it is expected to significantly save millions of dollars spent yearly on patients with treatment-resistant depression and that will lift this major burden off the shoulders of healthcare professionals. This study was designed to measure the effects of ketamine, an NMDA receptor antagonist, on patients with treatment-resistant MDD and to analyse the concept that makes it different and relatively safer than other major antidepressants like selective serotonin reuptake inhibitors, monoamine oxidase inhibitors and TCAs (tricyclic antidepressants).
 ...
PMID:Could ketamine be the answer to treating treatment-resistant major depressive disorder? 3287 73